The FDA has approved Zynyz (retifanlimab-dlwr) as the first programmed death receptor-1 inhibitor for first-line treatment of advanced squamous cell carcinoma of the anal canal.
A new systematic review evaluated 20 studies on artificial intelligence in bronchoscopy and found AI systems often performed as well as or better than human experts in tasks such as airway navigation and lymph node classification.